Nasdaq Bcel News Today

Atreca, Inc. (NASDAQ:BCEL – Get Free Report)’s share price was down 5.4% during mid-day trading on Wednesday . The company traded as low as $0.12 and last traded at $0.12. Approximately 834,698 shares traded hands during mid-day trading, a decline of 13% from the average daily volume of 963,973 shares. The stock had previously closed […]

Atreca (NASDAQ:BCEL – Get Free Report) was downgraded by Wedbush from an “outperform” rating to a “neutral” rating in a note issued to investors on Monday, Marketbeat Ratings reports. A number of other equities research analysts have also recently commented on the stock. HC Wainwright cut shares of Atreca from a “buy” rating to a […]

Atreca (NASDAQ:BCEL – Get Free Report) was downgraded by equities research analysts at Wedbush from an “outperform” rating to a “neutral” rating in a research report issued to clients and investors on Monday, MarketBeat Ratings reports. BCEL has been the topic of several other research reports. Stifel Nicolaus downgraded shares of Atreca from a “buy” […]

Stifel Nicolaus cut shares of Atreca (NASDAQ:BCEL – Free Report) from a buy rating to a hold rating in a research report released on Friday morning, MarketBeat Ratings reports. Separately, HC Wainwright lowered Atreca from a buy rating to a neutral rating in a research report on Friday. Two analysts have rated the stock with […]

Atreca, Inc. (NASDAQ:BCEL – Get Rating) shot up 3.2% during mid-day trading on Monday . The company traded as high as $1.05 and last traded at $1.03. 71,794 shares traded hands during trading, a decline of 51% from the average session volume of 146,446 shares. The stock had previously closed at $1.00. Analyst Upgrades and […]

Atreca, Inc. (NASDAQ:BCEL – Get Rating) – Equities research analysts at Wedbush raised their Q2 2023 earnings per share estimates for shares of Atreca in a research note issued to investors on Thursday, May 11th. Wedbush analyst R. Driscoll now expects that the company will post earnings per share of ($0.59) for the quarter, up […]

Atreca (NASDAQ:BCEL – Get Rating) and Mustang Bio (NASDAQ:MBIO – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership. Institutional & Insider Ownership 40.2% of Atreca shares are owned […]

Shares of Atreca, Inc. (NASDAQ:BCEL – Get Rating) were down 0.5% during trading on Tuesday . The company traded as low as $0.88 and last traded at $0.91. Approximately 58,366 shares changed hands during mid-day trading, a decline of 64% from the average daily volume of 162,452 shares. The stock had previously closed at $0.91. […]

HC Wainwright reiterated their buy rating on shares of Atreca (NASDAQ:BCEL – Get Rating) in a report released on Thursday, Benzinga reports. HC Wainwright currently has a $25.00 price objective on the stock. A number of other analysts have also commented on BCEL. Wedbush reissued an outperform rating and set a $4.00 price target on […]

EF Hutton Acquisition Co. I reissued their buy rating on shares of Atreca (NASDAQ:BCEL – Get Rating) in a research report released on Thursday morning, Benzinga reports. EF Hutton Acquisition Co. I currently has a $10.00 target price on the stock. Several other equities research analysts have also recently issued reports on the stock. Wedbush […]